Oesophageal Cancer Trial, Recruiting (NCT06385717)

Oesophageal Cancer Trial, Recruiting NCT06385717 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Oesophageal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06385717 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Oesophageal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with esophageal cancer and a procedure called endoscopic submucosal dissection (a type of minimally invasive procedure to remove tissue) has confirmed the cancer is at an early stage (specifically pT1a-MM or pT1b).
You do not have any serious medical reasons that would prevent you from receiving chemotherapy or radiation therapy.
You have chosen not to have surgery after your endoscopic procedure.
You are willing to sign a form giving your consent to take part in the trial.

Who may not be able to join:

You have a serious heart, brain, or lung condition, or your kidneys are not working properly.
You have been diagnosed with another type of cancer at any point in the past.
You have previously received radiation therapy or chemotherapy.
The trial researchers decide, for any reason, that it would not be appropriate for you to take part in the study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jing Xu, MD, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: 0086-0571-87783521

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06385717

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase: Not Applicable

Status: Recruiting

Condition: Oesophageal Cancer

Trial contact: 0086-0571-87783521

More information: https://clinicaltrials.gov/study/NCT06385717

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with esophageal cancer and a procedure called endoscopic submucosal dissection (a type of minimally invasive procedure to remove tissue) has confirmed the cancer is at an early stage (specifically pT1a-MM or pT1b).
You do not have any serious medical reasons that would prevent you from receiving chemotherapy or radiation therapy.
You have chosen not to have surgery after your endoscopic procedure.
You are willing to sign a form giving your consent to take part in the trial.

Who may not be able to join:

You have a serious heart, brain, or lung condition, or your kidneys are not working properly.
You have been diagnosed with another type of cancer at any point in the past.
You have previously received radiation therapy or chemotherapy.
The trial researchers decide, for any reason, that it would not be appropriate for you to take part in the study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Registry

ClinicalTrials.gov

Start date

1 May 2024

Est. completion

31 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of toxic events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov